Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tremelimumab vs Placebo in Second- or Third-line Unresectable Pleural or Peritoneal Malignant Mesothelioma
NCT01843374Phase 2Active, not recruiting
- Sponsor
- MedImmune
- Start
- May 2013
- Primary completion
- Jan 2016
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 19
01
Overview
A Phase 2 trial of tremelimumab in malignant mesothelioma, sponsored by MedImmune. Started May 2013; status: active, not recruiting.
02
Drugs
tremelimumab
03
Conditions
malignant mesothelioma
Beyond the preview
Go deeper on NCT01843374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01843374.